Advertisement

Advertisement

myelodysplastic syndromes

Targeting Errant Immune System Enzyme Kills Myelodysplastic Cells

Scientists have successfully targeted a malfunctioning immune system enzyme to kill diseased cells from patients with myelodysplastic syndrome (MDS), a precursor to acute myeloid leukemia (AML). Reporting their results in Cancer Cell, researchers say their successful laboratory tests in human MDS...

myelodysplastic syndromes

Study Sets Guidelines for Stem Cell Transplants in Older Patients with Myelodysplastic Syndromes

A new study by an international team of scientists provides the first statistically based guidelines for determining whether a stem cell transplant is appropriate for older patients with myelodysplastic syndromes (MDS), the most common blood disorders in people over 60 years of age, and frequently...

myelodysplastic syndromes

Moffitt Cancer Center Researchers Study Use of Dasatinib for Patients with High-risk MDS

Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib (Sprycel) for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed ...

Advertisement

Advertisement

Advertisement